Bergmann L, Weidmann E, Mitrou P S, Runne U, Keilholz U, Bartsch H H, Franks C R
Abteilung für Hämatologie, J.W. Goethe-Universität, Frankfurt/M.
Onkologie. 1990 Apr;13(2):137-40. doi: 10.1159/000216741.
In vitro, the combination of interleukin-2 (Il-2) with interferon-alpha (IFN-alpha) seems to act synergistically on the generation of lymphokine activated killer (LAK) cells. Due to this fact two clinical trials with the combination of Il-2 and IFN-alpha were initiated in malignant melanoma (MM) and renal cell cancer (RCC). Patients with disseminated MM were treated by a sequential application of 10 x 10(6) U/m2 rIFN-alpha 2b s.c. on days 1-7 followed by continuous intravenous infusion of 3 x 10(6) U/m2 rIl-2 on days 8-13 and 15-20. After a pause of 4 weeks the cycle was repeated. In advanced or disseminated RCC, the patients were treated with a daily alternating scheme of 10 x 10(6) U/m2 rIFN-alpha and rIl-2 as 1 h infusion 1 x /day for 14 days. The rIl-2 escalates intra- and interindividually beginning with a dose of 3 x 10(6) U/m2. The cycles were repeated after a pause of 3 and 4 weeks, respectively. The preliminary results show that the schedules are practicable and that the toxicity of the combination of rIl-2 and IFN-alpha does not accumulate. Within the MM group 3/11 evaluable patients achieved partial remission and 2/11 stable disease. In the RCC-group 2/5 evaluable patients achieved partial remission and 2/5 had stable disease so far.
在体外，白细胞介素-2（Il-2）与α干扰素（IFN-α）联合使用似乎对淋巴因子激活的杀伤细胞（LAK细胞）的生成具有协同作用。基于这一事实，开展了两项关于Il-2与IFN-α联合使用治疗恶性黑色素瘤（MM）和肾细胞癌（RCC）的临床试验。转移性MM患者在第1 - 7天接受皮下注射10×10⁶U/m²重组人α干扰素2b（rIFN-α 2b）的序贯治疗，随后在第8 - 13天和15 - 20天持续静脉输注3×10⁶U/m²重组人白细胞介素-2（rIl-2）。经过4周的间歇期后重复该周期。对于晚期或转移性RCC患者，采用每日交替方案，即10×10⁶U/m²的rIFN-α和rIl-2，每天1次，每次1小时静脉输注，共14天。rIl-2的剂量从3×10⁶U/m²开始，在个体内和个体间逐步递增。分别在3周和4周的间歇期后重复该周期。初步结果表明，该方案可行，且rIl-2与IFN-α联合使用的毒性不会累积。在MM组中，11例可评估患者中有3例达到部分缓解，2例病情稳定。在RCC组中，5例可评估患者中有2例达到部分缓解，2例目前病情稳定。
